Tell Congress: Investigate Big Pharma CEO and HHS Nominee Alex Azar

Common Cause
Daily Kos
People's Action
Public Citizen
Progress Ohio
Rights & Democracy VT
Rights & Democracy NH
Rootstrikers
The Nation
The Zero Hour
WV Citizen Action Group

To: All Members of Congress

We demand that you do everything in your power to investigate Alex Azar’s involvement in alleged price-fixing of the lifesaving medication insulin while he was a top executive at Eli Lilly. Everyday people need access to affordable medications and good health care. It would be unacceptable for a drug corporation CEO who has allegedly engaged in price-fixing to lead the Department of Health and Human Services.

In the next few weeks, the Senate will be voting on the confirmation of Alex Azar, a former executive of the drug corporation Eli Lilly, to replace Tom Price as Secretary of Health and Human Services.

During Alex Azar’s tenure at Eli Lilly, the drug corporation more than tripled the price of insulin from $74 to $269, even though the original patent for the drug expired more than 75 years ago. Data from Truven Health Analytics shows that Eli Lilly has increased the price of insulin in lockstep with Sanofi and Novo Nordisk, the other major drug corporations that produce the medication.

This lends credibility to allegations that Eli Lilly engaged in price-fixing under Alex Azar’s leadership. If true, Azar’s actions at Eli Lilly would not only have put lifesaving drugs out of reach for private consumers, they would also have increased costs for federal programs like Medicaid and Medicare.

The Senate confirmed Price – who later resigned for abuse of public funds – despite strong evidence Price had traded pharmaceutical stocks on inside tips while working on legislation related to the industry as a Republican Congressman. Now they want to confirm Azar, who played a major role in putting lifesaving medications out of reach and may even have engaged in price-fixing. Sign our petition and demand that Congress investigate Azar’s role in this alleged price-fixing scheme.